|Last Price$6.58||Day Change (%)2.97%|
|Open Price$6.39||Day Change ($)0.19|
|Day Range6.35–6.76||52-Week Range3.05–8.61|
As of Mon 8/3/2015 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.